News

The company’s investigational new drug application filing was announced on January 4, for a phase I clinical trial of a proprietary neural cell therapy product, HuCNS, in Batten

Scios Inc, another Johnson & Johnson company, currently markets the product on behalf of Centocor. ESP Pharma has now acquired distribution, manufacturing, development and marketing rights, all relevant

PXD101 is a small molecule histone deacetylase (HDAC) inhibitor being evaluated in advanced multiple myeloma. The companies reported that initiation of this phase II trial triggered an undisclosed

The compounds are PI3K inhibitors that were created under a joint drug discovery program. As part of the transduction signaling technology, these novel compounds could lead to new

These findings may offer new treatment options for Huntington’s disease, which currently has no cure. Huntington’s disease is a neurological disorder caused by a mutation in the gene

RhASB (galsulfase) is BioMarin’s investigational enzyme replacement therapy for the treatment of mucopolysaccharidosis VI (MPS VI), also known as Maroteaux-Lamy Syndrome, an inherited debilitating, life-threatening disease which affects

The company’s small molecule, melanocortin receptor subtype-4 (MC4) selective agonist was shown to reduce food intake and body weight and improve metabolic parameters in rodent models of obesity.

The study is an open label, phase I study that is evaluating 1D09C3 in patients with relapsed or refractory B-cell lymphomas who have failed prior standard therapy. The

The trial is based on promising clinical data from a previously conducted phase I/II clinical trial and is expected to enroll about 600 patients at 30-50 sites throughout